"1,000%+ pharmacy mark up" on generics
US pharmacies are marking up prices for generic drugs, often by over1,000%, says the Wall Street Journal (US edition), citing documents obtained by Mylan Labs, PMSI Scott-Levin and internal research. Markups on branded drugs are usually 10%-30%.
Despite the current controversy over prescription drug prices, high profits for some generics have escaped scrutiny because of competing market forces and health policy, and because those without insurance coverage do not have managed-care firms negotiating with the pharmacies for cheaper generic prices. Pharmacies charge $18.08 on average for generic haloperidol, a markup of 2,800%, reports PMSI Scott-Levin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze